Please ensure Javascript is enabled for purposes of website accessibility
Early Opportunities
Get in Before the Crowd

December 6, 2022

Sell Shockwave Medical (SWAV)

Today SWAV has dipped below support near 235, triggering my mental stop-loss level. We’ve previously locked in a profit of 30% on the first half of this position. Today, we’ll sell the second half to lock in a return that should be around 45%. Please note that I still like SWAV; however, the market is looking suspect once again and a “strong” stock moving below support isn’t one I want to be overly patient with. I will keep an eye on SWAV and consider adding it back in the future. SELL

Tyler Laundon is chief analyst of the limited-subscription advisory, Cabot Small-Cap Confidential and grand slam advisory Cabot Early Opportunities. He has spent his entire career managing, consulting and analyzing start-up and small-cap companies. His hands-on experience has taught Tyler that the development of a superior business model is the biggest factor in determining a company’s long-term success. Accordingly, his research focuses on assessing the viability of management’s growth strategies, trends in addressable markets and achievement of major developmental milestones.